Neurocrine Biosciences (NBIX) Capital Expenditures (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Capital Expenditures of $7.8 million for Q2 2026, down 37.6% year-over-year from $12.5 million in Q2 2025, and down 14.29% on a QoQ basis from $9.1 million in Q1 2026.
Neurocrine Biosciences (NBIX) Capital Expenditures (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Capital Expenditures for 17 years, with the latest figure at $7.8 million in Q2 2026.
- Capital Expenditures for Q2 2026 came in at $7.8 million, down 37.6% year-over-year; the trailing twelve-month figure through Jun 2026 was $27.7 million (down 28.24% YoY), and the FY2025 annual result was $34.0 million, down 10.99% from the prior year.
- Capital Expenditures slipped to $7.8 million in Q2 2026, from $9.1 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $13.2 million in Q3 2025 and troughed at -$2.4 million in Q4 2025.
- A 5-year average of $7.4 million and a median of $8.0 million in 2024 frame the typical range for Capital Expenditures.
- The widest annual swing landed in 2023, when Capital Expenditures jumped 547.06%; it then slumped 132.88% in 2025.
- A 5-year view of Capital Expenditures shows it stood at $1.8 million in 2022, then surged by 200.0% to $5.4 million in 2023, then soared by 35.19% to $7.3 million in 2024, then slumped by 132.88% to -$2.4 million in 2025, then surged by 425.0% to $7.8 million in 2026.
- Per Business Quant data, the three most recent Capital Expenditures figures were $7.8 million in Q2 2026, $9.1 million in Q1 2026, and -$2.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 8.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.80 Mn |
| Jun 30, 2026 | 7.80 Mn |
| Mar 31, 2026 | 1.40 Mn |
| Mar 31, 2026 | 1.40 Mn |
| Dec 31, 2025 | -2.40 Mn |
| Dec 31, 2025 | -2.40 Mn |
| Sep 30, 2025 | 34.50 Mn |
| Sep 30, 2025 | 34.50 Mn |
| Jun 30, 2025 | -8.80 Mn |
| Jun 30, 2025 | -8.80 Mn |
| Mar 31, 2025 | 10.70 Mn |
| Mar 31, 2025 | 10.70 Mn |
| Dec 31, 2024 | 37.40 Mn |
| Dec 31, 2024 | 37.40 Mn |
| Sep 30, 2024 | -2.50 Mn |
| Sep 30, 2024 | -2.50 Mn |
| Jun 30, 2024 | -7.90 Mn |
| Jun 30, 2024 | -7.90 Mn |
| Mar 31, 2024 | 11.20 Mn |
| Mar 31, 2024 | 11.20 Mn |